---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-015161"
form_type: "8-K"
ticker: "TENX"
cik: "0000034956"
company_name: "TENAX THERAPEUTICS, INC."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T09:07:20.759492+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tenax Therapeutics appoints Thomas A. McGauley as Interim CFO, effective Dec 2, 2024

## Summary
- Thomas A. McGauley appointed Interim CFO and principal financial/accounting officer, replacing Lawrence R. Hoffman.
- McGauley provides services through Danforth Advisors at $410 per hour with up to 4% annual increase.
- McGauley has 25+ years financial experience, including interim CFO at Galectin Therapeutics and manager at PwC.
- He holds a CPA and B.S.B.A in Accounting from Stonehill College; no familial relationships with officers or directors.

## SEC filing metadata
- accession: 0001654954-24-015161
- form_type: 8-K
- ticker: TENX
- cik: 0000034956
- company_name: TENAX THERAPEUTICS, INC.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/34956/000165495424015161/0001654954-24-015161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/34956/000165495424015161/tenx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-015161
- JSON: https://secwatch.observer/filing/0001654954-24-015161.json
- Plain text: https://secwatch.observer/filing/0001654954-24-015161.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.